Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 29

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Rheumatoid arthritis+1

Not yet recruiting

Testing the Safety of Combining Tocilizumab with Other Biologic Drugs in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Cardiff University

Systemic lupus erythematosus

Not yet recruiting

Comparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

Dermatitis atopic

Not yet recruiting

Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:University Of Michigan

Systemic scleroderma+2

Not yet recruiting

Study of B Cell Response to Tetanus Toxoid Vaccination in Patients with Systemic Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Leiden University Medical Center

Erysipelas

Not yet recruiting

Comparison of compression therapy alone versus compression therapy with phenoxymethylpenicillin for preventing recurrent erysipelas in lower limbs

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Phenoxymethylpenicillin
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Dermatitis atopic

Not yet recruiting

Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
  • Sponsor:Aclaris Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Skin dystrophy+1

Not yet recruiting

Study of botulinum toxin type A injections to prevent scarring in patients after heart surgery with sternotomy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Cutaneous T-cell lymphoma

Not yet recruiting

Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus+6

Not yet recruiting

Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:Region Skane

Malignant melanoma

Not yet recruiting

Long-term follow-up study of fianlimab and cemiplimab combination treatment in adult patients with melanoma

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Rheumatoid arthritis+1

Not yet recruiting

Evaluating Safety and Effectiveness of Combining Biologic Medications for Patients with Rheumatoid Arthritis and Psoriatic Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Cardiff University

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.